ABPI announces new president-elect
The Association of the British Pharmaceutical Industry (ABPI) has announced that Russel Abberley, the Vice President and General Manager of Amgen UK and Ireland, will become the organisation’s new president, after having held the role on an interim basis.
Abberley will take up the role on 13 May for a period of two years. He will help lead the ABPI in its mission to make the UK an attractive place for pharmaceutical companies and biotechs to develop and launch medicines. His immediate focus will remain on delivering a thriving UK life sciences ecosystem, where patients can access innovative medicines and vaccines and where the right conditions exist to attract global investment.
Abberley’s presidency of the ABPI comes ahead of the publication of the NHS 10-Year Plan and the Life Sciences Sector Plan, and his role could prove essential in helping the industry deliver on the government’s ambitions for health and economic growth.
Abberley has over 25 years of life science industry experience across a range of geographies. He has also served on the ABPI Board since July 2020 and has played a prominent leadership role in industry negotiations and engagements with the government over the past five years.
Abberley said: “I am proud of the UK’s strong legacy of leadership in life sciences and innovation – but there is a lot more we can do to ensure that UK patients can access innovative treatments. A proud advocate for our sector, I stand ready to work with government on delivering its ambition to make the UK a life sciences powerhouse. By working together, we can improve the health of the nation and generate much needed economic growth.”
Richard Torbett, ABPI Chief Executive added: “Russell has been great to work with as Acting President and is already a strong and valued member of our Board. I look forward to continuing our work together.”
Reece Armstrong, Editor, DDW
